NASDAQ:HLVX HilleVax (HLVX) Stock Forecast, Price & News $13.45 -0.03 (-0.22%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$13.20▼$13.5850-Day Range$11.59▼$15.5852-Week Range$11.35▼$23.10Volume46,199 shsAverage Volume88,393 shsMarket Capitalization$651.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media HilleVax MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish6.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.74Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.30) to ($3.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.0.90 out of 5 starsMedical Sector960th out of 972 stocksBiological Products, Except Diagnostic Industry154th out of 156 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for HilleVax. Previous Next 0.0 Short Interest Percentage of Shares Shorted6.71% of the float of HilleVax has been sold short.Short Interest Ratio / Days to CoverHilleVax has a short interest ratio ("days to cover") of 11.6, which indicates bearish sentiment.Change versus previous monthShort interest in HilleVax has recently increased by 5.81%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldHilleVax does not currently pay a dividend.Dividend GrowthHilleVax does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HLVX. Previous Next 2.1 News and Social Media Coverage News SentimentHilleVax has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for HilleVax this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for HLVX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, HilleVax insiders have not sold or bought any company stock.Percentage Held by Insiders29.30% of the stock of HilleVax is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.77% of the stock of HilleVax is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for HilleVax are expected to decrease in the coming year, from ($3.30) to ($3.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of HilleVax is -5.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of HilleVax is -5.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHilleVax has a P/B Ratio of 1.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About HilleVax (NASDAQ:HLVX) StockHilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. The company develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus and related illness. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.Read More HLVX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HLVX Stock News HeadlinesSeptember 26, 2023 | finance.yahoo.comHilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare ConferenceSeptember 25, 2023 | benzinga.comHilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional SharesOctober 1, 2023 | Legacy Research (Ad)Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”September 25, 2023 | finance.yahoo.comHilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional SharesSeptember 24, 2023 | americanbankingnews.comHilleVax (NASDAQ:HLVX) Shares Down 2.9% September 23, 2023 | finance.yahoo.comOwning 32% shares,institutional owners seem interested in HilleVax, Inc. (NASDAQ:HLVX),September 20, 2023 | benzinga.comWhy HilleVax Shares Are Trading LowerSeptember 20, 2023 | markets.businessinsider.comPre-market Movers: SPRY, SNTG, PODC, EXAI, BJDX…October 1, 2023 | Legacy Research (Ad)Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”September 19, 2023 | finance.yahoo.comHilleVax Announces Pricing of Public Offering of Common StockSeptember 19, 2023 | finance.yahoo.comHilleVax Announces Proposed Public Offering of Common StockAugust 30, 2023 | msn.comHilleVax: Takeda's Norovirus Vaccine SpinoutAugust 14, 2023 | bizjournals.comBiotech behind 2022's largest local IPO delays norovirus vaccineAugust 14, 2023 | msn.comHilleVax GAAP EPS of -$0.74August 14, 2023 | finanznachrichten.deHilleVax, Inc.: HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company ProgressAugust 14, 2023 | finance.yahoo.comHilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company ProgressJune 7, 2023 | finance.yahoo.comWall Street Analysts Predict a 56.76% Upside in HilleVax, Inc. (HLVX): Here's What You Should KnowJune 7, 2023 | finance.yahoo.comWall Street Analysts Predict a 56.76% Upside in HilleVax, Inc. (HLVX): Here's What You Should KnowMay 30, 2023 | markets.businessinsider.comStifel Nicolaus Sticks to Its Buy Rating for HilleVax, Inc (HLVX)May 25, 2023 | markets.businessinsider.comStifel Nicolaus Reaffirms Their Buy Rating on HilleVax, Inc (HLVX)May 22, 2023 | finance.yahoo.comHow Much Upside is Left in HilleVax, Inc. (HLVX)? Wall Street Analysts Think 87.76%May 16, 2023 | msn.comJP Morgan Maintains HilleVax (HLVX) Overweight RecommendationMay 16, 2023 | markets.businessinsider.comJ.P. Morgan Keeps Their Buy Rating on HilleVax, Inc (HLVX)May 13, 2023 | finanznachrichten.deHilleVax, Inc.: HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company ProgressMay 12, 2023 | msn.comHilleVax: Q1 Earnings InsightsMay 12, 2023 | finance.yahoo.comHilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company ProgressMay 9, 2023 | finance.yahoo.comHilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of DirectorsSee More Headlines Receive HLVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for HilleVax and its competitors with MarketBeat's FREE daily newsletter. Email Address HLVX Company Calendar Last Earnings8/14/2023Today10/01/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HLVX CUSIPN/A CIK1888012 Webwww.hillevax.com Phone617-213-5054FaxN/AEmployees62Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-159,810,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-36.52% Return on Assets-30.25% Debt Debt-to-Equity Ratio0.11 Current Ratio13.80 Quick Ratio13.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.01 per share Price / Book1.68Miscellaneous Outstanding Shares48,420,000Free Float34,231,000Market Cap$651.25 million OptionableNot Optionable Beta0.03 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Robert M. Hershberg M.D. (Age 61)Ph.D., Pres, CEO & Chairman Comp: $1.02MMr. Aditya Kohli Ph.D. (Age 35)COO & Director Comp: $782.44kMr. David A. Socks (Age 48)Chief Bus. Officer Comp: $709.59kMr. Shane A. Maltbie (Age 41)CFO & Treasurer Dr. Anju Chatterji Ph.D.Chief Technology OfficerMr. Paul S. Bavier J.D. (Age 51)Gen. Counsel, Sec. & Chief Admin. Officer Ms. Astrid Borkowski M.D. (Age 53)Ph.D., Chief Medical Officer Mr. Ozzie BergerSr. VP of Regulatory AffairsMore ExecutivesKey CompetitorsTarsus PharmaceuticalsNASDAQ:TARSAlectorNASDAQ:ALEC4D Molecular TherapeuticsNASDAQ:FDMTAnavex Life SciencesNASDAQ:AVXLAllogene TherapeuticsNASDAQ:ALLOView All CompetitorsInstitutional OwnershipBarclays PLCSold 2,869 shares on 9/21/2023Ownership: 0.015%Nuveen Asset Management LLCBought 16,066 shares on 8/16/2023Ownership: 0.102%Alliancebernstein L.P.Bought 12,150 shares on 8/15/2023Ownership: 0.031%Wells Fargo & Company MNBought 5,084 shares on 8/15/2023Ownership: 0.021%Royal Bank of CanadaBought 1,072 shares on 8/15/2023Ownership: 0.012%View All Institutional Transactions HLVX Stock - Frequently Asked Questions How have HLVX shares performed in 2023? HilleVax's stock was trading at $16.73 at the beginning of 2023. Since then, HLVX stock has decreased by 19.6% and is now trading at $13.45. View the best growth stocks for 2023 here. Are investors shorting HilleVax? HilleVax saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 672,000 shares, an increase of 5.8% from the August 31st total of 635,100 shares. Based on an average daily trading volume, of 58,000 shares, the days-to-cover ratio is presently 11.6 days. Currently, 6.7% of the shares of the company are sold short. View HilleVax's Short Interest. When is HilleVax's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our HLVX earnings forecast. How were HilleVax's earnings last quarter? HilleVax, Inc. (NASDAQ:HLVX) announced its quarterly earnings data on Monday, August, 14th. The company reported ($0.74) earnings per share for the quarter, topping analysts' consensus estimates of ($0.85) by $0.11. What ETFs hold HilleVax's stock? ETFs with the largest weight of HilleVax (NASDAQ:HLVX) stock in their portfolio include Morningstar US Small Growth (MSGR).ETFMG Treatments Testing and Advancements ETF (GERM). When did HilleVax IPO? (HLVX) raised $200 million in an initial public offering (IPO) on Friday, April 29th 2022. The company issued 11,765,000 shares at a price of $16.00-$18.00 per share. What is HilleVax's stock symbol? HilleVax trades on the NASDAQ under the ticker symbol "HLVX." How do I buy shares of HilleVax? Shares of HLVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is HilleVax's stock price today? One share of HLVX stock can currently be purchased for approximately $13.45. How much money does HilleVax make? HilleVax (NASDAQ:HLVX) has a market capitalization of $651.25 million. The company earns $-159,810,000.00 in net income (profit) each year or ($2.46) on an earnings per share basis. How can I contact HilleVax? The official website for the company is www.hillevax.com. The company can be reached via phone at 617-213-5054 or via email at ir@hillevax.com. This page (NASDAQ:HLVX) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding HilleVax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.